Presentations

Upcoming Events

GentiBio will be presenting at these upcoming meetings.

The American Association of Immunologists (AAI)
Boston, MA
April 15-19, 2026

Pediatric Endocrine Society (PES)
San Francisco, CA
April 30–May 3, 2026

American Society of Cell & Gene Therapy (ASGCT)
Boston, MA
May 11-15, 2026

Archived Conference Presentations

MAY 23, 2023

GNTI-122: Development of GNTI-122, a novel engineered regulatory T cell therapeutic, for future application in type 1 diabetes

OCTOBER 11, 2022

GNTI-122: Development and characterization of GNTI-122, an autologous engineered human regulatory T cell therapy for type 1 diabetes

JUNE 05, 2022

GNTI-122: Characterization and efficacy of engineered regulatory T-cell therapy, GNTI-122, for treating Type 1 Diabetes

MAY 16, 2022

GNTI-122 is a Dual-Engineered Regulatory T Cell Therapy Product for Type 1 Diabetes with Enhanced Stability, Tissue Specificity, and Tunable IL-2 Signaling

MAY 13, 2025

GNTI-932: A gut specific CAR-Engineered Regulatory T cell therapy to treat Inflammatory Bowel Disease

OCTOBER 01, 2025

ACR GNTI-350 CAR19 EngTregs for B and T cell mediated AID

APRIL 17, 2025

GNTI-350: CAR19 EngTregs offer broad capacity to modulate immune tolerance and improve safety in B and T cell mediated autoimmune disorders

MAY 13, 2025

GNTI-823: Allogeneic Engineered T Regulatory Cells Improve Disease Outcome in Preclinical Models of Acute Lung Injury

MAY 13, 2025

GNTI-823: Allogeneic Tissue Engineered Tregs for the Treatment of Ischemic Stroke and Neurodegenerative Diseases

JUNE 16, 2024

GNTI-823: A Tissue Engineered Treg Approach for the Treatment of Acute Ischemic and Inflammatory Diseases

MAY 31, 2024

GNTI-823: Adoptive Transfer of Murine Engineered T Regulatory Cells Ameliorates Disease in a Model of Lipopolysaccharide Induced Acute Lung Injury

MAY 07, 2024

GNTI-823: Characterization of Allogeneic Engineered Human Tissue-Tregs for Treatment of Acute Inflammatory Disease

APRIL 23, 2024

GNTI-823: Engineered Regulatory T cells ameliorate lung injury in the LPS model of acute lung injury

February 04, 2026

Keystone Emerging Cell Tx GentiBio IEE

OCTOBER 02, 2025

iPSC Summit Hypo-Immune Allogeneic EngTregs show long-term persistence

MAY 13, 2025

A Novel NK Inhibitor Provides “Best-in-Class” Protection of HLA Knockout Allogeneic Human Engineered Regulatory T Cells to Effectively Evade Immune Rejection

MAY 13, 2025

A stable Engineered Regulatory T cell therapy platform with modular targeting for autoimmune and inflammatory disorders

MAY 11, 2024

Stable Expression of FOXP3 and Core Tolerogenic Genes by Engineered Human Tregs

MAY 03, 2025

Development of Allogeneic Tissue Engineered Tregs for the Treatment of Ischemic Stroke and Acute Lung Injury

OCTOBER 24, 2023

A novel engineered Treg platform that addresses Treg stability, IL-2 signaling and targeting, for the treatment of autoimmune diseases

JUNE 20, 2023

Human Engineered Tregs maintain stability in inflammatory environment